Microdosing LSD Won’t Really Help Your ADHD, Trial Finds
People who took twice-weekly low doses of LSD experienced no greater improvement in their ADHD symptoms than people taking ...
IL-7 treatment shows promise in reducing lethal secondary infections in critically ill COVID-19 patients
A new study published in JCI Insight suggests that interleukin-7 (IL-7), a key immune-boosting cytokine, may help critically ...
Phase 2 trial reveals potential of DPP-1 inhibitor for bronchiectasis
The Lancet Respiratory Medicine published a phase 2 clinical study article on China's first DPP-1 inhibitor, HSK31858, led by ...
Medscape1d
Phase 2 Trial Supports TYK2 Inhibitor for Cutaneous Lupus, Paving Way for Pivotal Trials
After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...
The American Journal of Managed Care2d
Sotatercept Reduces Risk of Death, Transplant, or Hospitalization in Advanced PAH
Patients taking sotatercept had a 76% relative risk reduction in morbidity and mortality events compared with patients taking ...
CURE1d
Tagrisso May Improve Survival in Advanced EGFR-Mutant NSCLC
Tagrisso is associated with positive outcomes among patients with unresectable stage 3 EGFR-mutant non-small cell lung cancer ...
News-Medical.Net on MSN1d
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...